Galunisertib has demonstrated antifibrotic and antitumor activity in pancreatic cancer clinical trials (NCT02734160), though its potential interference with TGF-β’s immunomodulatory functions requires caution (27). Here, TGFB1 is linked to familial pancreatic carcinoma.